UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPRO | VAL |
|-----------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average bur | den |
| hours per response | 0.5 |

longer subject to Section $16.\ Form\ 4\ or\ Form\ 5$

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | pe Response | | | | | | | | | | | | | | | |
|--|---|-------------------------|---|--|---|--|---------------|---|--|------------------------------|--|--|---------------------------------|---|--|---|
| 1. Name and Address of Reporting Person* Chadha Deepak | | | | | 2. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI] | | | | | | : | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | |
| (Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021 | | | | | | | X Officer (give title below) Other (specify below) Chief Research & Dev. Officer | | | | |
| (Street) BOULDER, CO 80301 | | | | 4. If | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person | | | | | |
| (Ci | ty) | (State) | (Zip) | | | | Tal | ble I - Non-D | erivative S | Securiti | es Acqui | red, Disposed of, | or Beneficia | ally Owned | | |
| 1.Title of S (Instr. 3) | ecurity | | 2. Transaction Date (Month/Day/Ye | | 2A. Deemed Execution I any (Month/Day | | Code (Inst | | 4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5) | | of (D) | 5. Amount of Secu Dwned Following : Transaction(s) Instr. 3 and 4) | | C F | Ownership Form: | 7. Nature of Indirect Beneficial Ownership |
| | | | | (- | | | | ode V | Amount | (A) or (D) | Price | (mstr. 5 and 4) | | or Indirect (I) (I) (Instr. 4) | | |
| Reminder: | Report on a | separate fine for each | 100000 | | , 0 | | | Perso this fo | | ot requ | ired to r | collection of information of informa | | | SEC | 474 (9-02) |
| Reminder: | Report on a | separate fille for each | - Class of Securities o | | , 0 | ······································ | , - | Perso | | | | | | | SEC | 474 (9-02) |
| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date | Tabl 3A. Deemed Execution Date, if any | de II - D (e 4. Transac Code | Deriva | tive Securi uts, calls, w 5. Number Derivative Securities | ties Acarran | Perso this fo | orm are no ntly valid of cosed of, or convertible sable and e | ot requ OMB o | ired to r control n ficially Ov ties) | espond unless umber. wned and Amount of ng Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities | 10. Ownersl Form of | ip of Indire |
| 1. Title of Derivative | 2. Conversion | 3. Transaction Date | Tabl 3A. Deemed Execution Date, if | de II - D (e 4. Transac Code | Deriva | ative Securi uts, calls, w 5. Number Derivative | of 6 E (1 | Perso this fo curred cquired, Dis ats, options, o . Date Exerci expiration Da | orm are no ntly valid of cosed of, or convertible sable and e | ot requ OMB o | ired to r control n ficially Ov ties) 7. Title a Underlyi | espond unless umber. wned and Amount of ng Securities | 8. Price of Derivative | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s | 10. Ownersl Form of Derivati Security Direct (I or Indirect) | ip of Indire Benefici Ownersk (Instr. 4) |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price of Derivative | 3. Transaction Date | Tabl 3A. Deemed Execution Date, if any | de II - D (e 4. Transac Code | Deriva | tive Securi uts, calls, w 5. Number Derivative Securities Acquired (or Disposed (D) (Instr. 3, 4, and 5) | of 6 E (I | Perso this fo curred cquired, Dis ats, options, o . Date Exerci expiration Da | orm are no ntly valid of cosed of, or convertible sable and e | ot requ OMB of r Benef | ired to r control n ficially Ov ties) 7. Title a Underlyi | espond unless umber. wned and Amount of ng Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned Following Reported | 10. Ownersl Form of Derivati Security Direct (I or Indire | ip of Indire Benefici Ownersk (Instr. 4) |

| | Relationships | | | | | |
|--|---------------|--------------|-------------------------------|-------|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | |
| Chadha Deepak C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301 | | | Chief Research & Dev. Officer | | | |

Signatures

| /s/ Christine G. Long, Attorney-in-Fact for Deepak Chadha (power of attorney previously filed) | 06/14/2021 |
|--|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.